IGM Biosciences, Inc.
DelistedCIK 1496323fmd_0F1Y9BTX8JY6KADKJ9VNFZV08JManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Jun 30, 2025, 31 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|
| Research and development | 9 | 19 | 35 | 65 | 127 | 179 | 216 | 161 |
| Total operating expenses | 11 | 23 | 44 | 83 | 165 | 229 | 266 | 211 |
| Operating income | (11) | (23) | (44) | (83) | (165) | (228) | (263) | (209) |
| Other non-operating income (expense) | 0 | 0 | 1 | 2 | 0 | 7 | 18 | 13 |
| Income before taxes | – | – | – | – | (165) | (221) | (246) | (196) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Net income from continuing operations | – | – | – | – | (165) | (221) | (246) | (196) |
| Net income | (11) | (23) | (43) | (81) | (165) | (221) | (246) | (196) |